Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Gram-Positive Bacterial Infections
View Full LandscapeTarget Indication
Gram-Positive Bacterial Infections
Clinical Trial
NCT00081744Last updated: 12/13/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tigecycline Accord
Treatment of: - complicated skin and soft tissue infections, excluding diabetic foot infections - complicated intra-abdominal infections Tygacil should be used only in situations where it is known or suspected that other alternatives are not suitable
View on EMATigecycline Accord
Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4) Complicated intra-abdominal infections (cIAI) Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
View on EMA